DOCSLIB.ORG

FOI 169-1415 Document 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FOI 169-1415 Document 4 Special Access Scheme - Category A Notifications from 1 January 2014 to 31 January 2015 Title Record Number SASA - Thymus Extract R14/942930 SASA - Triclabendazole R14/1060082 SASA - Triclabendazole R14/1060081 SASA - Triclabendazole R14/1060080 SASA - Triclabendazole R14/1060079 SASA - Sincalide R14/1028424 SASA - Sincalide R14/1028423 SASA - Sincalide R14/1028422 SASA - Sincalide R14/1028421 SASA - Pristinamycin R14/149897 SASA- Pimozide R14/1022230 SASA - Natamycin R14/1060297 SASA - Indocyanine Green R15/100546 SASA - Indocyanine Green R15/100545 SASA - Indocyanine Green R15/100544 SASA - Indocyanine Green R15/100543 SASA - Indocyanine Green R15/100542 SASA - Indocyanine Green R15/100541 SASA - Indocyanine Green R15/100540 SASA - Indocyanine Green R15/100538 SASA - Hyoscine R14/1060252 SASA - Hyoscine R14/1060251 SASA - Hyoscine R14/1060250 SASA - Hyoscine R14/1060249 SASA - Hyoscine R14/1060248 SASA - Hyoscine R14/1060247 SASA - Hyoscine R14/1060246 SASA - Hyoscine R14/1060245 SASA - Hyoscine R14/1060244 SASA - Hyoscine R14/1060240 SASA - Fosfomycin R14/1065512 SASA - Flecainide R14/1060226 SASA - Flecainide R14/1060225 SASA - Flecainide R14/1060224 SASA - Flecainide R14/1060222 SASA - Flecainide R14/1060220 SASA - Flecainide R14/1060219 SASA - Flecainide R14/1060218 SASA - Flecainide R14/1060217 SASA - Flecainide R14/1060216 SASA - Flecainide R14/1060215 SASA - Flecainide R14/1060214 SASA - Flecainide R14/1060213 SASA - Flecainide R14/1060212 SASA - Flecainide R14/1060210 SASA - Flecainide R14/1060209 SASA - Flecainide R14/1060208 SASA - Flecainide R14/1060207 SASA - Flecainide R14/1060206 SASA - Flecainide R14/1060205 SASA - Flecainide R14/1060203 SASA - Flecainide R14/1060202 SASA - Flecainide R14/1060201 SASA - Flecainide R14/1060200 SASA - Flecainide R14/1060199 SASA - Flecainide R14/1060198 SASA - Flecainide R14/1060197 SASA - Flecainide R14/1060196 SASA - Flecainide R14/1060195 SASA - Flecainide R14/1060193 SASA - Flecainide R14/1060191 SASA - Flecainide R14/1060190 SASA - Flecainide R14/1060189 SASA - Flecainide R14/1060188 SASA - Flecainide R14/1060187 SASA - Flecainide R14/1060186 SASA - Flecainide R14/1060185 SASA - Flecainide R14/1060184 SASA - Felbamate R14/1022080 SASA - Felbamate R14/1022077 SASA - Fefitinib R14/1022083 SASA - Digoxin R14/1022213 SASA - Decitabine R14/1022205 SASA - Dasatinib R14/1022034 SASA - Dasatinib R14/1022031 SASA - Dasatinib R14/1022030 SASA - Chloroquine R14/1022271 SASA - Chloroquine R14/1022269 SASA - Chloroquine R14/1022266 SASA - Chloroquine R14/1022262 SASA - Chloroquine R14/1022260 SASA - Chloroquine R14/1022259 SASA - Chloroquine R14/1022255 SASA - Chloroquine R14/1022254 SASA - Chloroquine R14/1022252 SASA - Chloroquine R14/1022249 SASA - Chloroquine R14/1022247 SASA - Chloroquine R14/1022246 SASA - Chloroquine R14/1022242 SASA - Chloroquine R14/1022240 SASA - Cefoxitin R14/1181495 SASA - Carbimazole R14/149545 SASA - Calcium Chloride 10% R14/628639 SASA - Betaxolol R14/1021976 SASA - Betaxolol R14/1021975 SASA - Betaxolol R14/1021971 SASA - Betaxolol R14/1021969 SASA - Betaxolol R14/1021965 SASA - Betaxolol R14/1021963 SASA - Betaxolol R14/1021962 SASA - Betaxolol R14/1021960 SASA - Azacitidine R14/1022813 SASA - Azacitidine R14/1022812 SASA - Azacitidine R14/1022809 SASA - Azacitidine R14/1022807 SASA - Azacitidine R14/1022805 SASA - Amphotericin R14/746994 SASA - Amantadine R14/1021910 SASA - Alemtuzumab R14/1028321 SASA - Afatanib R14/1021929 SASA - Zoledronic acid R14/398564 SASA - Zidovudine R15/27033 SASA - Zidovudine R15/27029 SASA - Zidovudine R14/1244367 SASA - Zidovudine R14/1216396 SASA - Zidovudine R14/1216395 SASA - Zidovudine R14/1216394 SASA - Zidovudine R14/1216393 SASA - Zidovudine R14/1031090 SASA - Zidovudine R14/1031087 SASA - Zidovudine R14/1031086 SASA - Zidovudine R14/1031085 SASA - Zidovudine R14/1031084 SASA - Zidovudine R14/1031082 SASA - Zidovudine R14/1031081 SASA - Zidovudine R14/256517 SASA - Zidovudine R14/251444 SASA - Zanamivir R14/1216413 SASA - Zanamivir R14/1216412 SASA - Zanamivir R14/1216411 SASA - Zanamivir R14/1216410 SASA - Xylocaine R15/39392 SASA - Xylocaine R15/39391 SASA - Xylocaine R15/39390 SASA - Xylocaine R14/1216453 SASA - Xylocaine R14/1216452 SASA - Xylocaine R14/1216451 SASA - Xylocaine R14/1216450 SASA - Xylocaine R14/1216449 SASA - Xylocaine R14/1216448 SASA - Xylocaine R14/1216447 SASA - Xylocaine R14/1216446 SASA - Xylocaine R14/1216445 SASA - Xylocaine R14/1216441 SASA - Xylocaine R14/1216440 SASA - Xylocaine R14/1216439 SASA - Xylocaine R14/1216438 SASA - Xylocaine R14/1216437 SASA - Xylocaine R14/1216436 SASA - Xylocaine R14/1216435 SASA - Xylocaine R14/1216434 SASA - Xylocaine R14/1216433 SASA - Xylocaine R14/1216432 SASA - Xylocaine R14/1216431 SASA - Xylocaine R14/1216430 SASA - Xylocaine R14/1216429 SASA - Xylocaine R14/1216428 SASA - WHO MDT R14/1216461 SASA - WHO MDP pack R15/34127 SASA - WHO MB Pack R14/251520 SASA - VSD R15/27048 SASA - Vorinostat R14/1088388 SASA - Vorinostat R14/1088387 SASA - Vorinostat R14/1088386 SASA - Vorinostat R14/1088385 SASA - Vorinostat R14/235280 SASA - Vorinostat R14/235217 SASA - VNS & POA R14/251402 SASA - Vitamin C R14/1216470 SASA - Vitamin C R14/1216469 SASA - Vitamin A (Retinol) R14/1216480 SASA - Vitamin A (Retinol) R14/1216479 SASA - Vitamin A (Retinol) R14/1216478 SASA - Vitamin A (Retinol) R14/1216477 SASA - Vitamin A (Retinol) R14/1216476 SASA - Vitamin A (Retinol) R14/1216475 SASA - Vitamin A (Retinol) R14/1216473 SASA - Vitamin A R14/1216484 SASA - Vitamin A R14/1216482 SASA - Vitamin A R14/1216481 SASA - Vitamin A R14/1065830 SASA - Vitamin A R14/1065829 SASA - Vitamin A R14/1065828 SASA - Vitamin A R14/1065827 SASA - Vismodegib R14/1158813 SASA - Vinorelbine R14/1040715 SASA - Vindesine R14/1244376 SASA - Vindesine R14/1244373 SASA - Vindesine R14/1244372 SASA - Vindesine R14/1216499 SASA - Vindesine R14/1216498 SASA - Vindesine R14/1216497 SASA - Vindesine R14/1216496 SASA - Vindesine R14/1216495 SASA - Vindesine R14/1216494 SASA - Vindesine R14/1216493 SASA - Vindesine R14/1216492 SASA - Vindesine R14/1216491 SASA - Vindesine R14/1216490 SASA - Vindesine R14/1216489 SASA - Vindesine R14/1216488 SASA - Vindesine R14/1058694 SASA - Vindesine R14/1058693 SASA - Vindesine R14/1058692 SASA - Vindesine R14/256590 SASA - Vindesine R14/256509 SASA - Vindesine R14/251126 SASA - Vindesine R14/149893 SASA - Vincerinone R14/1061184 SASA - Vinblastine R14/251507 SASA - Vinblastine R14/251231 SASA - Vinblastine R14/251225 SASA - Verteporfin R14/1216555 SASA - Verteporfin R14/1216554 SASA - Verteporfin R14/1216553 SASA - Verteporfin R14/200182 SASA - Verapamil Hydrochloride R14/1216596 SASA - Verapamil Hydrochloride R14/1216594 SASA - Verapamil Hydrochloride R14/1216592 SASA - Verapamil Hydrochloride R14/1216589 SASA - Verapamil Hydrochloride R14/1216586 SASA - Verapamil Hydrochloride R14/1216578 SASA - Verapamil Hydrochloride R14/1216577 SASA - Verapamil Hydrochloride R14/1216576 SASA - Verapamil Hydrochloride R14/1216573 SASA - Verapamil Hydrochloride R14/1216572 SASA - Verapamil Hydrochloride R14/1216571 SASA - Verapamil Hydrochloride R14/1216570 SASA - Verapamil Hydrochloride R14/1216569 SASA - Verapamil Hydrochloride R14/1216567 SASA - Verapamil Hydrochloride R14/1216566 SASA - Verapamil Hydrochloride R14/1216565 SASA - Verapamil Hydrochloride R14/1216564 SASA - Verapamil Hydrochloride R14/1216563 SASA - Verapamil Hydrochloride R14/1216562 SASA - Verapamil Hydrochloride R14/1216560 SASA - Verapamil Hydrochloride R14/1216559 SASA - Verapamil Hydrochloride R14/1216558 SASA - Verapamil Hydrochloride R14/1026225 SASA - Verapamil Hydrochloride R14/1026224 SASA - Verapamil Hydrochloride R14/1026223 SASA - Verapamil Hydrochloride R14/1026222 SASA - Verapamil Hydrochloride R14/1026221 SASA - Verapamil Hydrochloride R14/1026220 SASA - Verapamil Hydrochloride R14/1026218 SASA - Verapamil Hydrochloride R14/1026217 SASA - Verapamil Hydrochloride R14/1026211 SASA - Verapamil Hydrochloride R14/1026210 SASA - Verapamil Hydrochloride R14/1026208 SASA - Verapamil Hydrochloride R14/1026207 SASA - Verapamil Hydrochloride R14/1026203 SASA - Verapamil Hydrochloride R14/1026202 SASA - Verapamil Hydrochloride R14/1026201 SASA - Verapamil Hydrochloride R14/1026200 SASA - Verapamil Hydrochloride R14/1026199 SASA - Verapamil Hydrochloride R14/1026198 SASA - Verapamil Hydrochloride R14/1026197 SASA - Verapamil Hydrochloride R14/1026196 SASA - Verapamil Hydrochloride R14/1026195 SASA - Verapamil Hydrochloride R14/1026194 SASA - Verapamil Hydrochloride R14/1026193 SASA - Verapamil Hydrochloride R14/1026192 SASA - Verapamil Hydrochloride R14/1026191 SASA - Verapamil Hydrochloride R14/1026190 SASA - Verapamil Hydrochloride R14/1026189 SASA - Verapamil Hydrochloride R14/1026188 SASA - Verapamil Hydrochloride R14/1026187 SASA - Verapamil Hydrochloride R14/1026186 SASA - Verapamil Hydrochloride R14/1026185 SASA - Verapamil Hydrochloride R14/1026184 SASA - Verapamil Hydrochloride R14/1026183 SASA - Verapamil Hydrochloride R14/1026182 SASA - Verapamil Hydrochloride R14/1026181 SASA - Verapamil Hydrochloride R14/1026180 SASA - Verapamil Hydrochloride R14/1026177 SASA - Verapamil Hydrochloride R14/1026176 SASA - Verapamil Hydrochloride R14/1026175 SASA - Verapamil Hydrochloride R14/1026174 SASA - Verapamil Hydrochloride R14/1026173 SASA - Verapamil Hydrochloride R14/1026172 SASA - Verapamil Hydrochloride R14/1026171 SASA - Verapamil Hydrochloride R14/1026170 SASA - Verapamil Hydrochloride R14/1026169 SASA - Verapamil Hydrochloride R14/1026168 SASA - Verapamil Hydrochloride R14/1026167 SASA - Verapamil
Load more

Recommended publications
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Kinevac® (Sincalide) For Injection 5 mcg/vial Diagnostic Cholecystokinetic Bracco Imaging Canada Date of Initial Approval: Montreal, Quebec July 2, 1996 Canada, H1J 2Z4 Date of Revision: October 30, 2019 Submission Control No: 231066 Product Monograph Kinevac® Page 1 of 14 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 1 INDICATIONS ................................................................................................................. 3 Pediatrics ........................................................................................................................ 3 Geriatrics ......................................................................................................................... 3 2 CONTRAINDICATIONS .................................................................................................. 3 3 DOSAGE AND ADMINISTRATION ................................................................................ 4 Recommended Dose and Dosage Adjustment ................................................................ 4 Reconstitution .................................................................................................................. 4 4 OVERDOSAGE ..............................................................................................................
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Chapter 12 Monographs of 99Mtc Pharmaceuticals 12
    Chapter 12 Monographs of 99mTc Pharmaceuticals 12 12.1 99mTc-Pertechnetate I. Zolle and P.O. Bremer Chemical name Chemical structure Sodium pertechnetate Sodium pertechnetate 99mTc injection (fission) (Ph. Eur.) Technetium Tc 99m pertechnetate injection (USP) 99m ± Pertechnetate anion ( TcO4) 99mTc(VII)-Na-pertechnetate Physical characteristics Commercial products Ec=140.5 keV (IT) 99Mo/99mTc generator: T1/2 =6.02 h GE Healthcare Bristol-Myers Squibb Mallinckrodt/Tyco Preparation Sodium pertechnetate 99mTc is eluted from an approved 99Mo/99mTc generator with ster- ile, isotonic saline. Generator systems differ; therefore, elution should be performed ac- cording to the manual provided by the manufacturer. Aseptic conditions have to be maintained throughout the operation, keeping the elution needle sterile. The total eluted activity and volume are recorded at the time of elution. The resulting 99mTc ac- tivity concentration depends on the elution volume. Sodium pertechnetate 99mTc is a clear, colorless solution for intravenous injection. The pH value is 4.0±8.0 (Ph. Eur.). Description of Eluate 99mTc eluate is described in the European Pharmacopeia in two specific monographs de- pending on the method of preparation of the parent radionuclide 99Mo, which is generally isolated from fission products (Monograph 124) (Council of Europe 2005a), or produced by neutron activation of metallic 98Mo-oxide (Monograph 283) (Council of Europe 2005b). Sodium pertechnetate 99mTc injection solution satisfies the general requirements of parenteral preparations stated in the European Pharmacopeia (Council of Europe 2004). The specific activity of 99mTc-pertechnetate is not stated in the Pharmacopeia; however, it is recommended that the eluate is obtained from a generator that is eluted regularly, 174 12.1 99mTc-Pertechnetate every 24 h.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe Et Al
    USOO6803046B2 (12) United States Patent (10) Patent No.: US 6,803,046 B2 Metcalfe et al. (45) Date of Patent: Oct. 12, 2004 (54) SINCALIDE FORMULATIONS OTHER PUBLICATIONS (75) Inventors: Edmund C. Metcalfe, Hillsborough, NJ Sitzmann, et al., “Cholecystokinin Prevents Parenteral (US); Jo Anna Monteferrante, Raritan Nutrition Induced Biliary Sludge in Humans.” Surgery, Township, NJ (US); Margaret Gynecology & Obstetrics, vol. 170, Jan. 1990, pp. 25-31. Newborn, Hamilton Township, NJ Teitelbaum et al., “Treatment of Parenteral Nutrition-ASSo (US); Irene Ropiak, Lawrenceville, NJ ciated Cholestasis with Cholecystokinin-Octapeptide,” (US); Ernst Schramm, North Journal of Pediatric Surgery, vol. 30, No. 7, Jul. 1995, pp. Brunswick, NJ (US); Gregory W. 1082-1085. White, Monmouth Junction, NJ (US); Moss and Amii, “New Approaches to Understanding the Julius P. Zodda, Mercerville, NJ (US) Etiology and Treatment of Total Parenteral Nutrition-ASSo ciated Cholestasis,” Seminars in Pediatric Surgery, vol. 8, (73) Assignee: Bracco International B.V., Amsterdam No. 3, Aug. 1999, pp. 140–147. (NL) Teitelbaum, "Parenteral Nutrition-ASSociated Cholestasis,” c: - Current Opinion in Pediatrics, vol. 9, 1997, pp. 270–275. (*) Notice: Subject to any State the SME, tly Teitelbaum and Tracy, “Parenteral Nutrition-Associated patent is extended or adjusted under Cholestasis,” Seminars in Pediatric Surgery, vol. 10, No. 2, U.S.C. 154(b) by 0 days. May 2001, pp. 72–80. Strickley, “Parenteral Formulations of Small Molecules (21) Appl. No.: 10/222,540 Therapeutics Marketed in the United States (1999) -Part (22) Filed: Aug. 16, 2002 1, PDA Journal of Pharmaceutical Science & Technology, e - Vs vol. 53, No. 6, Nov.-Dec. 1999, pp.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Drugs and Biologicals Fee Schedule
    Payment Allowance Limits for PEIA Effective January 1, 2013 through December 31, 2013 The absence or presence of a HCPCS code does not indicate PEIA coverage. Similarily, the inclusion of a payment limit does not indicate coverage by PEIA. processing the claim. Vaccine Infusion DME Infusion Blood Clotting HCPCS Code Short Description HCPCS Code Dosage Payment Limit AWP% Vaccine Limit AWP% Limit AWP% Blood limit Factor Notes 90371 Hep b ig, im 1 ML$ 104.73 90375 Rabies ig, im/sc 150 IU$ 206.47 90376 Rabies ig, heat treated 150 IU$ 197.46 90385 Rh ig, minidose, im 50 MCG$ 24.62 90585 Bcg vaccine, percut 50 MG$ 120.87 90586 Bcg vaccine, intravesical 1 EACH$ 120.87 90632 Hep a vaccine, adult im 1 ML$ 50.93 90654 Flu vaccine, intradermal, no preserv 0.1 ML$ 18.98 95 18.981 90655 Flu vaccine no preserv 6-35m, im 0.25 ML$ 16.46 95 16.456 90656 Flu vaccine no preserv 3 yo & >, im 0.50 ML$ 12.40 95 12.398 90657 Flu vaccine, 6-35 mo, im 0.25 ML$ 6.02 95 6.023 90660 Flu vaccine, nasal 0.2 ML$ 23.46 95 23.456 90662 Flu vacc prsv free inc antig 0.5 ML$ 30.92 95 30.923 90669 Pneumococcal vacc, 7 val im 0.5 ML$ 95.48 95 95.481 90670 Pneumococcal vacc, 13 val im 0.5 ML$ 137.03 95 137.028 90675 Rabies vaccine, im 1 ML$ 190.40 90691 Typhoid vaccine, im 0.5 ML$ 68.27 90703 Tetanus vaccine, im 0.5 ML$ 35.41 90714 Td vaccine no prsrv >/= 7 yo, im 0.5 ML$ 19.93 90715 Tdap => 7 yo, im 0.5 ML$ 33.35 90717 Yellow fever vaccine, sc 0.5 ML$ 71.49 90732 Pneumococcal vaccine 0.5 ML$ 65.77 95 65.774 90733 Meningococcal vaccine, sc 0.5 ML$ 106.49 90735 Encephalitis
    [Show full text]
  • Foi-276-1213-02.Pdf
    Application Date Application Drug Name Generic Drug Name Indication Status Approved neovascular age-related macular degeneration (AMD) as per the Novartis Lucentis ranibizumab APPROVED 27/11/2012 Pharmaceuticals Australia Pty Ltd protocol cholecalciferol moderate to severe Vitamin D deficiency APPROVED 2/07/2012 Cholecystokinin for imaging of the biliary tract APPROVED 12/09/2011 cholecystokinin Kinevac/ Sincalide imaging of the biliary tract APPROVED 12/09/2011 cholecystokinin Kinevac/ Sincalide for use in nuclear medicine biliary studies APPROVED 12/09/2011 Melatonin sleep disturbance in children with severe disabilities APPROVED 25/08/2011 Indocyanine Green retinal angiography APPROVED 13/09/2011 Cholecystokinin Sincalide, Kinevac for imaging of the biliary tract. APPROVED 13/09/2011 cholecystekinin Kinevac/ Sincalide use in imaging of the biliary tract APPROVED 13/09/2011 during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography. during vitreo-retinal suegery and for intravenous injection to perform ICG Indocyanine Green APPROVED 12/09/2011 angiography during vitreo-retinal surgery and for intravenous injection to perform ICG Indocyanine Green APPROVED 8/11/2011 angiography. Cholecystokinin Sincalide, Kinevac for nuclear medicine biliary studies. APPROVED 14/11/2011 Mafenide 5% Sulfamylon for wound management of deep partial and full thickness
    [Show full text]
  • Drugs Used As Interventional Agents in Nuclear Medicine
    THE UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO The University of New Mexico Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals VOLUMEVII, NUMBER2 Drugs Used as Interventional Agents in Nuclear Medicine by: Vivian S.bveless, PharmD, RPh, BCNP o The Univemi~ of New Mexico Health Sciencw Center Collcg. of ~armacy is mpprovd by the American Council on Pharmaceutical Wucation ~ a provider m@ of continuing pharmaceutical ducacion. Program No. 039-000-98-001 -HM. 2,5 Contnct Hours or .25 CWS Coorditi”ng Wifor and Director of Phrmacy Co&”nuing Educ&”on William B. Hladik III, MS, RPh College of Pharmacy University of New Mexico Health Sciences Center Assoctie ~tior and Production Spectitit Sharon 1. Magers Ramirez, Administrative Assistant II College of Pharmacy University of New Mexico Health Sciences Center Witotial Board George H Hinkle, MS, RPh, BCNP William B. Hladik III, MS, RPh Jeffrey P. Norenbtirg, MS, RPh, BCNP Laura L. Boles Ponto, PhD, RPh Timothy M. Quinton, PharmD, MS, RPh, BCNP Guwt Reviewer Sam C. Augustine, PharmD, RPh, BCNP While the advice and information in thi~ publication are believd to be true and accurate at press time, neither the author(s) nor the editor nor the publisher can accept any legat responsibility for my errom or omissions tbt may be made. Thc publisher makes no warranty, express or implied, with res~t to the material contained herein. Copyright 1998 University of New Mexico Health Sciences Center Pharmacy Continuing Hucation Albuquerque, New Mexico DRUGS USED AS INTERVENTIONAL AGENTS IN NUCLEAR MEDICINE STATEMENT OF OBJECTIVES The primary purpose of this lesson is to provide a basic understanding of drugs used as interventional agents in the practice of nuclear medicine.
    [Show full text]
  • ( N Am Am Pm Vpm 17 16
    US 20090202635A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0202635 A1 Scott (43) Pub. Date: Aug. 13, 2009 (54) DELIVERY SYSTEM, APPLICATION, AND Publication Classification METHOD (51) Int. Cl. (76) Inventor: Stephen Michael Scott, Tampa, FL A6IR 9/12 (2006.01) (US) A69/20 (2006.01) Correspondence Address: STEPHEN M. SCOTT (52) U.S. Cl. ............................ 424/468; 424/464; 424/45 515 BOSPHORUS AVE TAMPA, FL 33606 (US) (21) Appl. No.: 12/361,863 (57) ABSTRACT (22) Filed: Jan. 29, 2009 A sequenced biologically compatible delivery system, appli cation, and method is provided, which increases therapeutic Related U.S. Application Data care of animals by conveniently and effectively Supplying (60) Provisional application No. 61/027,265, filed on Feb. meticulous administration plans requiring sequential admin 8, 2008. istration of varying biologically active agents. 14 15 1 O 16 22 ( N AM AM PM VPM 17 16 88: SH: 8 21 2O 9 Patent Application Publication Aug. 13, 2009 Sheet 1 of 10 US 2009/0202635 A1 ( N AM AM PM VPM II 88: 888 21 2 O 9 Patent Application Publication Aug. 13, 2009 Sheet 2 of 10 US 2009/0202635 A1 F.G. 2A FIG. 2C-2G 30.3 32 3334 3. |Niles (III OOOOOOOss 'eofooooo.OOOOOOO 4 O 36 3. Coolooloo 38 37 3 O FIG. 2B 3. FIG. IIC Patent Application Publication Aug. 13, 2009 Sheet 3 of 10 US 2009/0202635 A1 FIG. 38 37 43 30 FIG. 2G Patent Application Publication Aug. 13, 2009 Sheet 4 of 10 US 2009/0202635 A1 FIG.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • List of Pharamaceutical Peptides Available from ADI
    List of Pharamaceutical Peptides Available from ADI ADI has highly purified research grade/pharma grade pharmaceutical peptides available for small research scale or in bulk (>Kg scale). (See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2704 Catalog# Product Description Catalog# Product Description PP-1000 Abarelix (Acetyl-Ser-Leu-Pro-NH2; MW:1416.06) PP-1410 Growth Hormone-releasing factor, GRF (human) PP-1010 ACTH 1-24 (Adrenocorticotropic Hormone human) Acetate PP-1420 Hexarelin PP-1020 Alarelin Acetate PP-1430 Histrelin Acetate PP-1030 Angiotensin PP-1440 Lepirudin PP-1040 Angiotensin II Acetate PP-1450 Leuprolide PP-1050 Antide Acetate PP-1460 Leuprorelin Acetate PP-1060 Argipressin Acetate PP-1470 Lipopeptide Acetate PP-1070 Argireline Acetate PP-1480 Lypressin PP-1080 Atosiban Acetate PP-1490 Lysipressin Acetate PP-1090 Aviptadil PP-1500 Matrixyl Acetate PP-1100 Bivalirudin Trifluoroacetate PP-1510 Melanotan I, Acetate PP-1110 Buserelin acetate PP-1520 Melanotan II, MT-II, Acetate PP-1120 Copaxone acetate (Glatiramer acetate) PP-1530 Mechano Growth Factor, MGF, TFA PP-1130 Carbetocin acetate PP-1540 Nafarelin Acetate PP-1140 Cetrorelix Acetate PP-1550 Nesiritide Acetate PP-1150 Corticotropin-releasing factor, CRF (human, rat) Acetate PP-1560 Octreotide Acetate PP-1160 Corticotropin-releasing factor, CRF (ovine) PP-1570 Ornipressin Acetate Trifluoroacetate PP-1580 Oxytocin Acetate PP-1170 Deslorelin Acetate PP-1590 Palmitoyl Pentapeptide PP-1180 Desmopressin Acetate PP-1610 Pentagastrin Ammonium
    [Show full text]
  • USP Endotoxin Limits for Common Injectables
    Pharma&Biotech USP Endotoxin Limits for Common Injectables Updated as of August 2011 For reference use only Pharma&Biotech Updated as of August 2011. For reference use only. USP Endotoxin Limits This information is subject to the disclaimer included on page 13. for Common Injectables This table is for informational purposes only. Endotoxin limits should be set on an individual product basis, using the formula found in the Pharmacopeias (Endotoxin Limit = K/M). Description Endotoxin Limit A Acepromazine Maleate Injection 4.5 EU / mg Acetazolamide for Injection 0.5 EU / mg Acetic Acid Irrigation 0.5 EU / ml Acyclovir for Injection 0.174 EU / mg Adenosine Injection (continuous peripheral intravenous infusion) 5.95 EU / mg Adenosine Injection (rapid intravenous) 11.62 EU / mg Alcohol in Dextrose Injection 0.5 EU / ml Alfentanil Injection 10 EU / ml Alprostadil Injection 0.05 EU / µg Alteplase for Injection 1 EU / mg Amifostine for Injection 0.2 EU / mg Amikacin Sulfate Injection 0.33 EU / mg Aminocaproic Acid Injection 0.05 EU / mg Aminohippurate Sodium Injection 0.04 EU / mg Aminopentamide Sulfate Injection 25 EU / mg Aminophylline Injection 1 EU / mg Ammonium Chloride Injection (of Chloride) 1.72 mEq Cl Amobarbital Sodium for Injection 0.4 EU / mg Amoxicillin, Sterile and Suspension 0.25 EU / mg Amphotericin B for Injection (for Intrathecal) 0.9 EU / mg Amphotericin B for Injection (for Parenterals) 5 EU / mg Ampicillin and Sulbactam for Injection 0.17 EU / (1 mg of mix of amp and sulb - 0.67 and 0.33 mg, respectively) Ampicillin for Injection
    [Show full text]